Inhibikase Therapeutics Files 8-K/A Amendment
Ticker: IKT · Form: 8-K/A · Filed: Apr 2, 2024 · CIK: 1750149
Sentiment: neutral
Topics: amendment, personnel, corporate-governance
TL;DR
Inhibikase filed an amendment to its 8-K, updating info on exec changes and financials.
AI Summary
Inhibikase Therapeutics, Inc. filed an amendment (8-K/A) on April 2, 2024, to a previous report originally dated January 16, 2024. This amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing provides updated information regarding changes in the company's board and executive officers, which can impact corporate governance and strategic direction.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, primarily updating procedural and personnel information rather than announcing new material events.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- January 16, 2024 (date) — Original report date
- April 2, 2024 (date) — Amendment filing date
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A amends items related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
What was the original report date that this 8-K/A is amending?
The original report date that this 8-K/A is amending was January 16, 2024.
What is the filing date of this amendment?
This amendment was filed on April 2, 2024.
What is the principal executive office address for Inhibikase Therapeutics, Inc.?
The principal executive office address is 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339.
What is the business phone number for Inhibikase Therapeutics, Inc.?
The business phone number is (678) 392-3419.
Filing Stats: 1,360 words · 5 min read · ~5 pages · Grade level 12.8 · Accepted 2024-04-02 17:12:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
- $345,000 — Receive a base salary at the rate of $345,000 per annum (the "CFO Base Salary"); Re
- $2.16 — mon stock at an exercise price equal to $2.16 which was the fair market value of the
Filing Documents
- d821381d8ka.htm (8-K/A) — 37KB
- d821381dex991.htm (EX-99.1) — 103KB
- 0001193125-24-084902.txt ( ) — 303KB
- ikt-20240116.xsd (EX-101.SCH) — 3KB
- ikt-20240116_lab.xml (EX-101.LAB) — 19KB
- ikt-20240116_pre.xml (EX-101.PRE) — 12KB
- d821381d8ka_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Number Description 99.1 Employment Agreement between Inhibikase Therapeutics, Inc. and Garth Lees-Rolfe, dated as of April 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 2, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer